No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.4x · 10Y median 1.8x · 7th percentile · as of Sep 11, 2026
Annualized revenue (TTM) · by quarter, last 19
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-26T00:15:46.996Z. Latest historical point 2026-09-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for GE HealthCare Technologies Inc. (GEHC) stock was $66.63 as of Sep 25, 2026, 4:00 PM EDT, up 0.38% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -17.9% · 3-year avg -1.2%/yr
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions.
Medical - Devices · Chicago, IL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 4, 2026
37 days away
EPS Estimate
1.21
Revenue Est.
$5.35B
Last Quarter Results
EPS
$1.13
vs Estimate
$1.04
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GEHC | $30.10B | $66.63 | +0.38% | -17.85% | N/A | N/A | N/A |
| 2ZTS | $29.79B | $71.05 | +1.11% | -50.14% | -17.75% | +4.74% | vs GEHC |
| 3CNC | $30.53B | $61.80 | -0.19% | +94.98% | +2.15% | +7.11% | vs GEHC |
| 4MTD | $30.55B | $1511.64 | -0.49% | +0.84% | -4.09% | +12.77% | vs GEHC |
| 5MDLN | $29.34B | $34.70 | +0.12% | N/A | N/A | N/A | vs GEHC |
| 6ALC | $31.44B | $64.47 | -0.14% | -16.69% | -4.31% | N/A | vs GEHC |
TTM
1.49
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$5.29B
vs Estimate
$5.26B
Consensus Rating
Based on 18 analysts
Average Price Target
$82.50
+23.8% upside
Low
$70.00
Current
$66.63
High
$96.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.18 | $1.20 | $1.24 | 10 |
| Quarter ending Dec 2026 | $1.58 | $1.60 | $1.64 | 9 |
| Quarter ending Mar 2027 | $1.12 | $1.14 | $1.16 | 6 |
| Quarter ending Jun 2027 | $1.23 | $1.25 | $1.27 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $4.90 | $4.93 | $5.00 | 12 |
| FY 2027 | $5.16 | $5.44 | $5.58 | 12 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $5.27B | $5.35B | $5.39B | 10 |
| Quarter ending Dec 2026 | $5.85B | $5.94B | $5.98B | 10 |
| Quarter ending Mar 2027 | $5.29B | $5.36B | $5.43B | 9 |
| Quarter ending Jun 2027 | $5.43B | $5.51B | $5.57B | 9 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $21.56B | $21.72B | $21.83B | 15 |
| FY 2027 | $22.46B | $22.73B | $22.86B | 14 |
